{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:07:27Z","timestamp":1776456447249,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.2119\/molmed.2016.00218","type":"journal-article","created":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T09:49:13Z","timestamp":1484992153000},"page":"841-849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate A\u03b2 Peptides"],"prefix":"10.1186","volume":"22","author":[{"given":"Val\u00e9rie","family":"Vingtdeux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Chandakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M","family":"Acker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Marambaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"2201841_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1326-8-36","volume":"8","author":"CA Lemere","year":"2013","unstructured":"Lemere CA. (2013) Immunotherapy for Alzheimer\u2019s disease: hoops and hurdles. Mol. Neurodegener. 8:36.","journal-title":"Mol. Neurodegener."},{"key":"2201841_CR2","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","volume":"85","author":"T Wisniewski","year":"2015","unstructured":"Wisniewski T, Go\u00f1i F. (2015) Immunotherapeutic approaches for Alzheimer\u2019s disease. Neuron. 85:1162\u201376.","journal-title":"Neuron"},{"key":"2201841_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jamda.2016.06.009","volume":"17","author":"RM Sterner","year":"2016","unstructured":"Sterner RM, Takahashi PY, Yu Ballard AC. (2016) Active Vaccines for Alzheimer Disease Treatment. J. Am. Med. Dir. Assoc. 17: 862.e811\u201365.","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"2201841_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe DJ. (2001) Alzheimer\u2019s disease: genes, proteins, and therapy. Physiol. Rev. 81:741\u201366.","journal-title":"Physiol. Rev."},{"key":"2201841_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1046\/j.1471-4159.1995.65041431.x","volume":"65","author":"F Checler","year":"1995","unstructured":"Checler F. (1995) Processing of the beta-amyloid precursor protein and its regulation in Alzheimer\u2019s disease. J. Neurochem. 65:1431\u201344.","journal-title":"J. Neurochem."},{"key":"2201841_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1601-183X.2005.00086.x","volume":"4","author":"P Marambaud","year":"2005","unstructured":"Marambaud P, Robakis NK. (2005) Genetic and molecular aspects of Alzheimer\u2019s disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav. 4:134\u201346.","journal-title":"Genes Brain Behav."},{"key":"2201841_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron M. (2010) Alzheimer\u2019s disease: strategies for disease modification. Nat. Rev. Drug. Discov. 9:387\u201398.","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2201841_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 372:216\u201323.","journal-title":"Lancet"},{"key":"2201841_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1620\/tjem.220.95","volume":"220","author":"T Tabira","year":"2010","unstructured":"Tabira T. (2010) Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J. Exp. Med. 220:95\u2013106.","journal-title":"Tohoku J. Exp. Med."},{"key":"2201841_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1586\/14737175.2015.995637","volume":"15","author":"H Hampel","year":"2015","unstructured":"Hampel H, et al. (2015) Advances in the therapy of Alzheimer\u2019s disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev. Neurother. 15:83\u2013105.","journal-title":"Expert Rev. Neurother."},{"key":"2201841_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J. (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 76:185\u2013205.","journal-title":"Ann. Neurol."},{"key":"2201841_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/alzrt233","volume":"6","author":"TE Golde","year":"2014","unstructured":"Golde TE. (2014) Open questions for Alzheimer\u2019s disease immunotherapy. Alzheimers Res. Ther. 6:3.","journal-title":"Alzheimers Res. Ther."},{"key":"2201841_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","volume":"6","author":"B Strooper De","year":"2010","unstructured":"De Strooper B, Vassar R, Golde T. (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6:99\u2013107.","journal-title":"Nat. Rev. Neurol."},{"key":"2201841_CR14","doi-asserted-by":"crossref","first-page":"17082","DOI":"10.1016\/S0021-9258(18)41896-0","volume":"267","author":"H Mori","year":"1992","unstructured":"Mori H, Takio K, Ogawara M, Selkoe DJ. (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer\u2019s disease. J. Biol. Chem. 267:17082\u20136.","journal-title":"J. Biol. Chem."},{"key":"2201841_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0896-6273(95)90301-1","volume":"14","author":"TC Saido","year":"1995","unstructured":"Saido TC, et al. (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 14:457\u201366.","journal-title":"Neuron"},{"key":"2201841_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00401-010-0690-1","volume":"120","author":"E Portelius","year":"2010","unstructured":"Portelius E, et al. (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer\u2019s disease. Acta Neuropathol. 120:185\u201393.","journal-title":"Acta Neuropathol."},{"key":"2201841_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1471-4159.2009.05950.x","volume":"109","author":"J Sevalle","year":"2009","unstructured":"Sevalle J, et al. (2009) Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J. Neurochem. 109:248\u201356.","journal-title":"J. Neurochem."},{"key":"2201841_CR18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/nm.1872","volume":"14","author":"S Schilling","year":"2008","unstructured":"Schilling S, et al. (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer\u2019s disease-like pathology. Nat. Med. 14:1106\u201311.","journal-title":"Nat. Med."},{"key":"2201841_CR19","doi-asserted-by":"publisher","first-page":"34186","DOI":"10.1074\/jbc.M501694200","volume":"280","author":"A Piccini","year":"2005","unstructured":"Piccini A, et al. (2005) Beta-amyloid is different in normal aging and in Alzheimer disease. J. Biol. Chem. 280:34186\u201392.","journal-title":"J. Biol. Chem."},{"key":"2201841_CR20","doi-asserted-by":"publisher","first-page":"7072","DOI":"10.1021\/bi900818a","volume":"48","author":"D Schlenzig","year":"2009","unstructured":"Schlenzig D, et al. (2009) Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry. 48:7072\u20138.","journal-title":"Biochemistry"},{"key":"2201841_CR21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature11060","volume":"485","author":"JM Nussbaum","year":"2012","unstructured":"Nussbaum JM, et al. (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-\u03b2. Nature. 485:651\u20135.","journal-title":"Nature"},{"key":"2201841_CR22","doi-asserted-by":"publisher","first-page":"10871","DOI":"10.1021\/bi990563r","volume":"38","author":"W He","year":"1999","unstructured":"He W, Barrow CJ. (1999) The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry. 38:10871\u20137.","journal-title":"Biochemistry"},{"key":"2201841_CR23","doi-asserted-by":"publisher","first-page":"12393","DOI":"10.1021\/bi0612667","volume":"45","author":"S Schilling","year":"2006","unstructured":"Schilling S, et al. (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry. 45:12393\u20139.","journal-title":"Biochemistry"},{"key":"2201841_CR24","doi-asserted-by":"publisher","first-page":"e0143647","DOI":"10.1371\/journal.pone.0143647","volume":"10","author":"C Dammers","year":"2015","unstructured":"Dammers C, et al. (2015) Structural Analysis and Aggregation Propensity of Pyroglutamate A\u03b2(3\u201340) in Aqueous Trifluoroethanol. PLoS One. 10: e0143647.","journal-title":"PLoS One."},{"key":"2201841_CR25","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1046\/j.1471-4159.2002.01107.x","volume":"82","author":"C Russo","year":"2002","unstructured":"Russo C, et al. (2002) Pyroglutamate-modified amyloid beta-peptides\u2014AbetaN3(pE)\u2014strongly affect cultured neuron and astrocyte survival. J. Neurochem. 82:1480\u20139.","journal-title":"J. Neurochem."},{"key":"2201841_CR26","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1471-4159.2012.07707.x","volume":"121","author":"D Schlenzig","year":"2012","unstructured":"Schlenzig D, et al. (2012) N-terminal pyroglutamate formation of A\u03b238 and A\u03b240 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. J. Neurochem. 121:774\u201384.","journal-title":"J. Neurochem."},{"key":"2201841_CR27","doi-asserted-by":"publisher","first-page":"12790","DOI":"10.1523\/JNEUROSCI.1794-11.2011","volume":"31","author":"A Alexandru","year":"2011","unstructured":"Alexandru A, et al. (2011) Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A\u03b2 is induced by pyroglutamate-A\u03b2 formation. J. Neurosci. 31:12790\u2013801.","journal-title":"J. Neurosci."},{"key":"2201841_CR28","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.1074\/jbc.M115.655183","volume":"291","author":"AP Gunn","year":"2016","unstructured":"Gunn AP, et al. (2016) Amyloid-\u03b2 Peptide A\u03b2 3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. J. Biol. Chem. 291:6134\u201345.","journal-title":"J. Biol. Chem."},{"key":"2201841_CR29","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1016\/j.neurobiolaging.2015.08.021","volume":"36","author":"JL Frost","year":"2015","unstructured":"Frost JL, et al. (2015) An anti-pyroglutamate-3 A\u03b2 vaccine reduces plaques and improves cognition in APPswe\/PS1AE9 mice. Neurobiol Aging. 36:3187\u201399.","journal-title":"Neurobiol Aging."},{"key":"2201841_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00401-014-1287-x","volume":"127","author":"TA Bayer","year":"2014","unstructured":"Bayer TA, Wirths O. (2014) Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer\u2019s disease. Acta Neuropathol. 127:787\u2013801.","journal-title":"Acta Neuropathol."},{"key":"2201841_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13024-016-0115-2","volume":"11","author":"H Cynis","year":"2016","unstructured":"Cynis H, Frost JL, Crehan H, Lemere CA. (2016) Immunotherapy targeting pyroglutamate-3 A\u03b2: prospects and challenges. Mol. Neurodegener. 11:48.","journal-title":"Mol. Neurodegener."},{"key":"2201841_CR32","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","volume":"28","author":"HR Shinefield","year":"2010","unstructured":"Shinefield HR. (2010) Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. Vaccine. 28:4335\u20139.","journal-title":"Vaccine"},{"key":"2201841_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","volume":"39","author":"M Br\u00f6ker","year":"2011","unstructured":"Br\u00f6ker M, Costantino P, De Tora L, McIntosh ED, Rappuoli R. (2011) Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals. 39:195\u2013204.","journal-title":"Biologicals"},{"key":"2201841_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.4161\/hv.23224","volume":"9","author":"I Caro-Aguilar","year":"2013","unstructured":"Caro-Aguilar I, et al. (2013) Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Hum. Vaccin. Immunother. 9:488\u201396.","journal-title":"Hum. Vaccin. Immunother."},{"key":"2201841_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00401-010-0759-x","volume":"121","author":"V Vingtdeux","year":"2011","unstructured":"Vingtdeux V, Davies P, Dickson DW, Marambaud P. (2011) AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer\u2019s disease and other tauopathies. Acta Neuropathol. 121:337\u201349.","journal-title":"Acta Neuropathol."},{"key":"2201841_CR36","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1242\/jcs.167270","volume":"128","author":"V Vingtdeux","year":"2015","unstructured":"Vingtdeux V, et al. (2015) CALHM1 ion channel elicits amyloid-\u03b2 clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain. J. Cell Sci. 128:2330\u20138.","journal-title":"J. Cell Sci."},{"key":"2201841_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/CVI.00387-10","volume":"18","author":"S Rondini","year":"2011","unstructured":"Rondini S, et al. (2011) Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi. Clin. Vaccine Immunol. 18:460\u20138.","journal-title":"Clin. Vaccine Immunol."},{"key":"2201841_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0952-7915(95)80033-6","volume":"7","author":"HG Rammensee","year":"1995","unstructured":"Rammensee HG. (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7:85\u201396.","journal-title":"Curr. Opin. Immunol."},{"key":"2201841_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neulet.2011.09.071","volume":"505","author":"CP Sullivan","year":"2011","unstructured":"Sullivan CP, et al. (2011) Pyroglutamate-A\u03b2 3 and 11 colocalize in amyloid plaques in Alzheimer\u2019s disease cerebral cortex with pyroglutamate-A\u03b2 11 forming the central core. Neurosci. Lett. 505:109\u201312.","journal-title":"Neurosci. Lett."},{"key":"2201841_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/alzrt237","volume":"6","author":"B Winblad","year":"2014","unstructured":"Winblad B, Graf A, Riviere ME, Andreasen N, Ryan JM. (2014) Active immunotherapy options for Alzheimer\u2019s disease. Alzheimers Res. Ther. 6:7.","journal-title":"Alzheimers Res. Ther."},{"key":"2201841_CR41","doi-asserted-by":"publisher","first-page":"41517","DOI":"10.1074\/jbc.M110.178707","volume":"285","author":"O Wirths","year":"2010","unstructured":"Wirths O, et al. (2010) Identification of low molecular weight pyroglutamate Abeta oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J. Biol. Chem. 285:41517\u201324.","journal-title":"J. Biol. Chem."},{"key":"2201841_CR42","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB Demattos","year":"2012","unstructured":"Demattos RB, et al. (2012) A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron. 76:908\u201320.","journal-title":"Neuron"},{"key":"2201841_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.intimp.2015.09.012","volume":"29","author":"MJ McCluskie","year":"2015","unstructured":"McCluskie MJ, et al. (2015) Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates. Int Immunopharmacol. 29:663\u201371.","journal-title":"Int Immunopharmacol."},{"issue":"4","key":"2201841_CR44","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3233\/JAD-150376","volume":"51","author":"F Pasquier","year":"2016","unstructured":"Pasquier F, et al. (2016) Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer\u2019s Disease. J. Alzheimers Dis. 2016;51(4):1131\u201343.","journal-title":"J. Alzheimers Dis."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2016.00218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.2119\/molmed.2016.00218\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.molmed.org\/content\/pdfstore\/16_218_Vingtdeux.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2016.00218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T08:14:31Z","timestamp":1658477671000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2016.00218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2201841"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2016.00218","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/084913","asserted-by":"object"}]},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"8 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}